| 產品描述： | Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective CGRP receptor antagonist. |
| 靶點： |
CGRP receptor;CGRPReceptor |
| 體內研究： |
CGRP-(8-37) is effective in alleviating mechanical and thermal allodynia in a dose-dependent manner. The 50 nM dose is most efficacious for both forelimb and hindlimb responses. The period of efficacy is 10 min to onset for a duration of 20 min. Post-drug washout responses are not statistically significant compared to pre-drug responses. Intrathecal administration of 5 nmol or 10 nmol of CGRP-(8-37), but not 1 nmol, induces a significant increase in hindpaw withdrawal latency. Intrathecal administration of CGRP-(8-37) not only reverses the SP-induced decrease in latency to both withdrawal responses but also mediates a significant increase in response latency compared to basal levels |
| 參考文獻： |
1. Bennett AD, et al. Alleviation of mechanical and thermal allodynia by CGRP(8-37) in a rodent model of chroniccentral pain. Pain. 2000 May;86(1-2):163-75. 2. Yu LC, et al. The calcitonin gene-related peptide antagonist CGRP8-37 increases the latency to withdrawalresponses in rats. Brain Res. 1994 Aug 8;653(1-2):223-30. |
| 溶解性： |
H2O : 25 mg/mL (7.99 mM; Need ultrasonic) |
| 保存條件： |
-20°C |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
0.32 ml |
1.599 ml |
3.197 ml |
| 5 mM |
0.064 ml |
0.32 ml |
0.639 ml |
| 10 mM |
0.032 ml |
0.16 ml |
0.32 ml |
| 50 mM |
0.006 ml |
0.032 ml |
0.064 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京